Impel NeuroPharma intros migraine treatment Trudhesa
Impel NeuroPharma is offering Trudhesa (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) for the acute treatment of migraine with or without aura in adults.
Trudhesa is now available through Trudhesa Direct, a streamlined, customized, end-to-end process that provides hassle-free prescribing, savings, and home delivery. The digital pharmacy partners, Carepoint Pharmacy and Phil, facilitate the process beginning with e-prescribing and automatic enrollment of eligible, commercially-insured patients in the Trudhesa Direct Savings Program to obtain Trudhesa.
Once the pharmacy partners receive the e-prescription, patients will be notified via digital communications that their prescription has been processed and receive their medication via convenient, free, home delivery.
[Read more: FDA OKs ImpelNeuro Pharma's Trudhesa]
“We are excited and proud to launch Trudhesa within weeks of FDA approval. Trudhesa utilizes our pioneering pod technology to optimize delivery of DHE to the upper nasal space, giving migraine patients what they want—rapid, sustained, and consistent relief with one dose, self-administered, anytime, anywhere,” said Adrian Adams, chairman and CEO of Impel NeuroPharma. “Trudhesa is being made available via Trudhesa Direct, a streamlined process that includes automatic enrollment in the patient savings program for eligible, commercially insured patients. We look forward to working with our digital pharmacy partners to deliver Trudhesa seamlessly to patients at home, so it’s there when they need it.”
With each Trudhesa prescription, patients will receive four single-use products, each comprised of a pod device and a DHE vial packaged in a compact case. Most patients on Trudhesa achieve pain relief with one single dose.
“Our company, Carepoint Pharmacy, was built to provide patients with a simple and patient-first pharmacy experience that makes getting prescriptions easy, fast and reliable. When patients are dealing with the unpredictability of a condition like migraine, we offer assurance that their medication will arrive quickly, straight to their home, for convenience they can trust,” said Bhavesh Patel, Carepoint Pharmacy CEO.
[Read more: Teva launches Ajovy auto-injector device]
“Phil provides an efficient and value-driven experience for patients to get timely and affordable access to their medications," said Deepak Thomas, founder and CEO of Phil. "The challenges in this space reach far beyond the patient, and our goal is to simplify this complex ecosystem to deliver positive outcomes for all stakeholders.”
Impel has established a Patient Assistance Program for eligible patients with financial hardship or limited or no insurance. For more information, please visit here.